EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
de Rijdt, Thomas
Linked to EAHP Statements
Section 1 – Introductory Statements and Governance: Statements 1.1, 1.6
Section 4 – Clinical Pharmacy Services: Statement 4.1
Section 5 – Patient Safety and Quality Assurance: Statement 5.11
ACPE UAN: 0475-0000-21-005-L04-P. A knowledge based activity.
Abstract
Biologics in cancer care have enhanced the therapeutic options for clinicians in the management of oncologic therapy. Monoclonal antibodies (mAbs) are employed as targeted treatment and also to resolve therapy-related hematologic deficiencies. With the patents set to expire for several medications, biosimilars therapeutic proteins offer the potential to increase access to therapies and refuse cancer costs for patients and healthcare systems, while providing safety and efficacy profiles consistent with their respective reference or originator products and for which there are no clinically meaningful differences between the two products in terms of safety, purity and potency.
Biosimilar development programs for therapeutics including bevacizumab, cetuximab, rituximab, and trastuzumab; and supportive care products including epoetin alfa, filgrastim, and pegfilgrastim, are currently ongoing.
Moreover, biosimilars may offer additional advantages such as supply-chain benefits, patient-access support networks and assistance with reimbursement administration, as well as specialist pharmacy services.
Such potential services and advantages can only be provided if assessment and procurement systems reflect criteria beyond price, thereby it is important for healthcare professionals to have a good understanding of biosimilars, their development, regulatory approval processes and clinical utility, including the rules of switching and reswitching issues.
Hospital pharmacist can play a key role in the continued and increased use of biosimilars in cancer therapy. It is important to educate patients and ensure the quality use of medicines to avoid confusion. They could also run a patient-centred pharmacovigilance framework within the hospital to monitor and report outcomes and any adverse events associated with all biological therapies. Besides, they could have a driver’s seat to procurement strategies to cover the high cost, high volume biologics products.
Learning objectives
After this Synergy session, participants should be able to:
• advise how to implement and provide monitoring of biosimilars used in oncology;
• discuss and collaborate with other HCPs on specific issues relating to the optimum uses in the hospital area;
• assess the financial impact of oncology biosimilars on healthcare systems and be able to give a pharmacoeconomic view.
Educational need addressed
This is relevant for hospital pharmacists working in oncology therapeutic area.
Keywords: new drugs, biosimilars, cancer therapy, monoclonal antibodies, switching, monitoring, oncology.
